HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...
Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results